October 6, 2023 10:52 AM EDT

Regeneron pays $100M milestone to Alnylam; NIH awards Clene $45M; Biohaven raises $258M

Jaimy Lee

Deputy Editor

Max Gelman

Senior Editor

Regeneron pays out $100M proof-of-principle milestone: Regeneron said Thursday it will take a $100 million charge in the third quarter after paying out a development …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regeneron pays $100M milestone to Alnylam; NIH awards Clene $45M; Biohaven raises $258M

Jaimy Lee

Deputy Editor

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Sanofi introduces new 340B payment model — report

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Re­gen­eron pays $100M mile­stone to Al­ny­lam; NIH awards Clene $45M; Bio­haven rais­es $258M

Deputy Editor

Senior Editor

Sign up to read this article for free.

Regeneron pays $100M milestone to Alnylam; NIH awards Clene $45M; Biohaven raises $258M